Sutro Biopharma STRO Operating Lease Liabilities (Total)
Operating Lease Liabilities (Total) at other companies
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.
The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sutro Biopharma's operating lease liabilities (total).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sutro Biopharma's operating lease liabilities (total)?
- Sutro Biopharma (STRO) reported operating lease liabilities (total) of $13.63M in Q1 2026.
- How has Sutro Biopharma's operating lease liabilities (total) changed year-over-year?
- Sutro Biopharma's operating lease liabilities (total) decreased by 36.3% year-over-year, from $21.4M to $13.63M.
- What is the long-term trend for Sutro Biopharma's operating lease liabilities (total)?
- Over 4 years (2021 to 2025), Sutro Biopharma's operating lease liabilities (total) has grown at a -16.5% compound annual growth rate (CAGR), from $32.26M to $15.67M.
- What does operating lease liabilities (total) mean?
- This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.